ZANAFLEX CAPSULES Rx
Generic Name and Formulations:
Tizanidine HCl 2mg, 4mg, 6mg; caps.
Indications for ZANAFLEX CAPSULES:
Muscle spasticity (due to its short duration of action reserve for when relief is most important).
Initially: usually 4mg, may increase by 2–4mg as needed every 6–8 hrs to a max of 3 doses in 24hrs; max 12mg/dose and 36mg/day. Renal impairment (CrCl <25mL/min): reduce dose. May sprinkle contents of capsules on applesauce (may affect absorption). Tabs and caps not bioequivalent under fed conditions. See literature.
Concomitant fluvoxamine, ciprofloxacin.
Hepatic dysfunction. Monitor ophthalmic and liver function (aminotransferases at baseline, 1, 3, 6 months, then periodically) and for orthostatic hypotension. Renal dysfunction. Cardiovascular disease. Avoid abrupt cessation. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Avoid other α2-agonists (eg, clonidine). Hypotension possible with other antihypertensives. Avoid concomitant use with other CYP1A2 inhibitors (eg, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, other fluoroquinolones, oral contraceptives, acyclovir, ticlopidine, zileuton); if clinically necessary, use caution. May potentiate CNS depression with alcohol, baclofen, benzodiazepines, other CNS depressants.
Dry mouth, somnolence, asthenia, dizziness, UTI, constipation, liver injury or elevated liver enzymes, vomiting, speech disorder, blurred vision, dyskinesia, nervousness, pharyngitis, hypotension, bradycardia, hallucinations/psychosis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC